Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 7 points (0.0%) at 16,563 as of Tuesday, Aug. 12, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,349 issues advancing vs. 1,605 declining with 179 unchanged. The Health Services industry currently sits down 0.1% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Smith & Nephew ( SNN), up 1.6%, Intuitive Surgical ( ISRG), up 1.4%, WellPoint ( WLP), up 0.9%, Cigna ( CI), up 0.8% and Boston Scientific ( BSX), up 0.5%. On the negative front, top decliners within the industry include Abbott Laboratories ( ABT), down 1.2%, Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.1%, HCA Holdings ( HCA), down 0.7%, St Jude Medical ( STJ), down 0.6% and Aetna ( AET), down 0.5%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Charles River Laboratories International In ( CRL) is one of the companies pushing the Health Services industry higher today. As of noon trading, Charles River Laboratories International In is up $1.62 (2.9%) to $58.37 on heavy volume. Thus far, 330,812 shares of Charles River Laboratories International In exchanged hands as compared to its average daily volume of 425,200 shares. The stock has ranged in price between $56.76-$58.48 after having opened the day at $56.81 as compared to the previous trading day's close of $56.75. Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. Charles River Laboratories International In has a market cap of $2.7 billion and is part of the health care sector. Shares are up 7.0% year-to-date as of the close of trading on Monday. Currently there are 5 analysts who rate Charles River Laboratories International In a buy, no analysts rate it a sell, and 11 rate it a hold. TheStreet Ratings rates Charles River Laboratories International In as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Charles River Laboratories International In Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.